Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.66 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.54 |
| ▸ | EGFR | P00533 | 3/20 | 0.50 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.50 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.49 |
| ▸ | ABCC1 | P33527 | 3/20 | 0.49 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.49 |
| ▸ | CDC7 | O00311 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL221437 | 1.00 | RET (0.66) | RETKDRROCK2EGFRMKNK1 | |
| SCHEMBL3580880 | 0.92 | RET (0.64) | RETKDRROCK2ABCG2ABCB1 | |
| SCHEMBL3588668 | 0.89 | RET (0.61) | RETKDRROCK2EGFRABCG2 | |
| SCHEMBL3593329 | 0.89 | RET (0.62) | RETKDRROCK2EGFRABCG2 | |
| SCHEMBL13154698 | 0.88 | RET (0.66) | RETKDRROCK2EGFRABCG2 | |
| SCHEMBL3583259 | 0.87 | ROCK2 (0.64) | RETKDRROCK2ABCG2ABCB1 | |
| SCHEMBL13154702 | 0.84 | RET (0.72) | RETKDRROCK2EGFRMKNK1 | |
| SCHEMBL3581389 | 0.84 | RET (0.61) | RETKDRROCK2EGFRABCG2 | |
| SCHEMBL3808492 | 0.83 | ROCK2 (0.59) | RETROCK2EGFRABCG2ABCB1 | |
| SCHEMBL3587684 | 0.83 | TGFBR1 (0.56) | KDRROCK2MKNK1ABCG2ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117120055-A | Combination therapy comprising a JAK pathway inhibitor and a ROCK inhibitor | 因赛特公司 | 2023-11-24 | — | — | CN | disclosed |
| EP-4274578-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | Incyte Corporation (US) | 2023-11-15 | — | — | EP | disclosed |
| WO-2022150676-A1 | COMBINATION THERAPY COMPRISING JAK PATHWAY INHIBITOR AND ROCK INHIBITOR | INCYTE CORPORATION (US) | 2022-07-14 | — | — | WO | disclosed |